找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Resistance to Immunotherapeutic Antibodies in Cancer; Strategies to Overco Benjamin Bonavida Book 2013 Springer Science+Business Media New

[复制链接]
查看: 11895|回复: 44
发表于 2025-3-21 16:46:22 | 显示全部楼层 |阅读模式
书目名称Resistance to Immunotherapeutic Antibodies in Cancer
副标题Strategies to Overco
编辑Benjamin Bonavida
视频video
概述Summarizes common and unique features of mAbs against various cancers.Explores the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs.Covers the pot
丛书名称Resistance to Targeted Anti-Cancer Therapeutics
图书封面Titlebook: Resistance to Immunotherapeutic Antibodies in Cancer; Strategies to Overco Benjamin Bonavida Book 2013 Springer Science+Business Media New
描述​​​​The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.
出版日期Book 2013
关键词Rituximab; antibody-drug conjugates; cancer drug resistance; mABs; monoclonal antibody; antibodies
版次1
doihttps://doi.org/10.1007/978-1-4614-7654-2
isbn_softcover978-1-4899-8732-7
isbn_ebook978-1-4614-7654-2Series ISSN 2196-5501 Series E-ISSN 2196-551X
issn_series 2196-5501
copyrightSpringer Science+Business Media New York 2013
The information of publication is updating

书目名称Resistance to Immunotherapeutic Antibodies in Cancer影响因子(影响力)




书目名称Resistance to Immunotherapeutic Antibodies in Cancer影响因子(影响力)学科排名




书目名称Resistance to Immunotherapeutic Antibodies in Cancer网络公开度




书目名称Resistance to Immunotherapeutic Antibodies in Cancer网络公开度学科排名




书目名称Resistance to Immunotherapeutic Antibodies in Cancer被引频次




书目名称Resistance to Immunotherapeutic Antibodies in Cancer被引频次学科排名




书目名称Resistance to Immunotherapeutic Antibodies in Cancer年度引用




书目名称Resistance to Immunotherapeutic Antibodies in Cancer年度引用学科排名




书目名称Resistance to Immunotherapeutic Antibodies in Cancer读者反馈




书目名称Resistance to Immunotherapeutic Antibodies in Cancer读者反馈学科排名




单选投票, 共有 0 人参与投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 21:51:15 | 显示全部楼层
Emily L. Williams,Sean H. Lim,Stephen A. Beers,Peter W. Johnson,Jonathan C. Strefford,Martin J. Glenonen, die mit Formen arbeiten.Bildet eine ideale Brücke von .Die „Geometrie und ihre Anwendungen“ ist für Personen geschrieben, die von relativ einfachen Problemen der ebenen Geometrie bis hin zu schwierigeren Aufgaben der Raumgeometrie Interesse an geometrischen Zusammenhängen haben..Ähnlich wie be
发表于 2025-3-22 01:37:24 | 显示全部楼层
发表于 2025-3-22 07:33:17 | 显示全部楼层
发表于 2025-3-22 10:41:35 | 显示全部楼层
发表于 2025-3-22 12:56:33 | 显示全部楼层
Peter Hersey,Stuart Gallagher,Branka Mijatovund Grundschulalter zugeschrieben. Das Projekt . widmet sich daran anknüpfend der übergeordneten Frage, wie individuelle Vorgehensweisen bei der Erstellung konkreter Bauwerke mit den räumlichen Vorstellungen von Vor- und Grundschulkindern zusammenhängen. Im vorliegenden Beitrag werden theoretische B
发表于 2025-3-22 19:37:36 | 显示全部楼层
发表于 2025-3-22 22:17:41 | 显示全部楼层
发表于 2025-3-23 02:12:36 | 显示全部楼层
Understanding the Mechanisms of Resistance to Rituximab: Paving the Road for the Development of Thenovel therapeutic strategies to overcome or circumvent rituximab-resistance in B-cell lymphoma. Pre-clinical models to study rituximab-resistance have been generated and characterized. Moreover, repeated exposure of lymphoma cells to rituximab, not only results in a decrease in rituximab anti-tumor
发表于 2025-3-23 08:43:03 | 显示全部楼层
Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Prototmalignant and malignant B cells. Rituximab is currently the standard therapy when used in combination with chemotherapy (CHOP). However, like other therapeutics, a subset of patients initially does not respond and a subset responding patients develops resistance to further treatments. Such patients
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-9 17:58
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表